UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 13.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 80,196 shares of the specialty pharmaceutical company’s stock after selling 12,343 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Supernus Pharmaceuticals were worth $2,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Commonwealth Equity Services LLC grew its stake in shares of Supernus Pharmaceuticals by 3.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock valued at $273,000 after purchasing an additional 350 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the last quarter. GAMMA Investing LLC grew its position in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares during the period. Louisiana State Employees Retirement System raised its position in Supernus Pharmaceuticals by 2.2% in the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after acquiring an additional 600 shares during the period. Finally, Assetmark Inc. raised its position in Supernus Pharmaceuticals by 2.8% in the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after acquiring an additional 908 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $36.17 on Friday. The firm has a fifty day moving average price of $35.30 and a 200-day moving average price of $31.94. The stock has a market cap of $2.00 billion, a PE ratio of 33.80 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period in the previous year, the business earned ($0.29) earnings per share. The business’s revenue was up 14.2% on a year-over-year basis. On average, research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several analyst reports. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 in the last three months. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.